Serum Profile of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
Serum Profile of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
Epilepsy affects 0.7% of the general population and 15-20% of patients develop drug
 resistance. The temporal lobe epilepsy (TLE) is the most common symptomatic focal epilepsies
 with a particularly high rate of drug (about 20 to 30%). In this type of epilepsy, where
 feasible, surgical removal of the home is the best therapeutic outcome.

 Mechanisms of epileptogenesis and drug resistance are still mysterious. Of recent clinical
 and experimental studies have shown that dysfunction of the blood-brain barrier (BBB)
 contributes to epileptogenesis and drug resistance. It is now recognized that cytokines
 exacerbate the excitability and permeability of the BBB, which was recently confirmed by
 studies showing that treatment of inflammation reduces epileptogenesis. Moreover, we have
 described an association between pathological angiogenesis and BBB permeability in the tissue
 of patients with excision of drug-resistant TLE. With experimental models, it was revealed an
 activation of the VEGF-VEGFR2 by seizures leading to rapid degradation of the BBB.

 The investigators hypothesis is that the identification of factors involved in BBB
 permeability may designate potential targets for drug-resistant partial epilepsy.
Inclusion Criteria:

 -  Patient with temporal lobe epilepsy (TLE)

 -  Patient with epilepsy for at least two years. Arm 1: Patient with drug-resistant TLE
 proved potentially a candidate for surgery.

 Arm 2: Patient with TLE seizure-free for 12 months or more

 Exclusion Criteria:

 -  Patient with a scalable general pathology may lead to increased inflammatory markers:
 neoplasia, chronic inflammatory diseases etc. ...

 -  Patient with neurological history other than epilepsy with evolutionary potential or
 likely to interfere with the inflammatory markers